Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NBIX
- Price
- 137.37
- Stock movement up
- +1.96 (1.45%)
- Company name
- Neurocrine Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 13.70B
- Ent value
- 14.62B
- Price/Sales
- 5.11
- Price/Book
- 4.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 32.00
- Forward P/E
- 14.97
- PEG
- -
- EPS growth
- 53.45%
- 1 year return (CAGR)
- -5.83%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NBIX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 32.00 |
| Price to OCF | 21.51 |
| Price to FCF | 23.09 |
| Price to EBITDA | 20.58 |
| EV to EBITDA | 21.97 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.11 |
| Price to Book | 4.56 |
| EV to Sales | 5.45 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 99.71M |
| EPS (TTM) | 4.18 |
| FCF per share (TTM) | 5.79 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.68B |
| Gross profit (TTM) | 2.64B |
| Operating income (TTM) | 550.20M |
| Net income (TTM) | 428.00M |
| EPS (TTM) | 4.18 |
| EPS (1y forward) | 9.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.37% |
| Operating margin (TTM) | 20.51% |
| Profit margin (TTM) | 15.95% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 340.20M |
| Net receivables | 728.00M |
| Total current assets | 2.16B |
| Goodwill | 0.00 |
| Intangible assets | 35.70M |
| Property, plant and equipment | 566.20M |
| Total assets | 4.27B |
| Accounts payable | 119.90M |
| Short/Current long term debt | 428.40M |
| Total current liabilities | 638.00M |
| Total liabilities | 1.26B |
| Shareholder's equity | 3.00B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 636.80M |
| Capital expenditures (TTM) | 43.70M |
| Free cash flow (TTM) | 593.10M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 14.25% |
| Return on Assets | 10.03% |
| Return on Invested Capital | 14.25% |
| Cash Return on Invested Capital | 19.75% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 135.57 |
| Daily high | 137.73 |
| Daily low | 134.94 |
| Daily Volume | 800K |
| All-time high | 155.63 |
| 1y analyst estimate | 179.70 |
| Beta | 0.27 |
| EPS (TTM) | 4.18 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Feb 2026 |
Downside potential
Loading...
Downside potential data
| NBIX | S&P500 | |
| Current price drop from All-time high | -11.73% | -0.89% |
| Highest price drop | -42.89% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -15.50% | -2.49% |
| Avg time to new high | 64 days | 6 days |
| Max time to new high | 193 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
13.70B
Marketcap category
Large-cap
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Employees
1800
Website
Investor relations
-
SEC filings
CEO
Kevin Charles Gorman
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page